These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 26941365

  • 1. Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.
    Penney KL, Pettersson A, Shui IM, Graff RE, Kraft P, Lis RT, Sesso HD, Loda M, Mucci LA.
    Cancer Epidemiol Biomarkers Prev; 2016 May; 25(5):745-9. PubMed ID: 26941365
    [Abstract] [Full Text] [Related]

  • 2. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.
    Ma C, Wang X, Dai JY, Turman C, Kraft P, Stopsack KH, Loda M, Pettersson A, Mucci LA, Stanford JL, Penney KL.
    Cancer Epidemiol Biomarkers Prev; 2023 Oct 02; 32(10):1436-1443. PubMed ID: 37555839
    [Abstract] [Full Text] [Related]

  • 3. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.
    Prostate; 2013 Feb 15; 73(3):242-9. PubMed ID: 22821767
    [Abstract] [Full Text] [Related]

  • 4. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
    Luedeke M, Rinckleb AE, FitzGerald LM, Geybels MS, Schleutker J, Eeles RA, Teixeira MR, Cannon-Albright L, Ostrander EA, Weikert S, Herkommer K, Wahlfors T, Visakorpi T, Leinonen KA, Tammela TLJ, Cooper CS, Kote-Jarai Z, Edwards S, Goh CL, McCarthy F, Parker C, Flohr P, Paulo P, Jerónimo C, Henrique R, Krause H, Wach S, Lieb V, Rau TT, Vogel W, Kuefer R, Hofer MD, Perner S, Rubin MA, Agarwal AM, Easton DF, Al Olama AA, Benlloch S, PRACTICAL consortium, Hoegel J, Stanford JL, Maier C.
    Hum Mol Genet; 2016 Dec 15; 25(24):5490-5499. PubMed ID: 27798103
    [Abstract] [Full Text] [Related]

  • 5. Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.
    Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, Fiorentino M, Giovannucci EL, Loda M, Mucci LA.
    Cancer Epidemiol Biomarkers Prev; 2018 Feb 15; 27(2):193-200. PubMed ID: 29167279
    [Abstract] [Full Text] [Related]

  • 6. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
    J Pathol; 2007 May 15; 212(1):91-101. PubMed ID: 17385188
    [Abstract] [Full Text] [Related]

  • 7. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
    Graff RE, Judson G, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA, Pettersson A.
    Prostate; 2017 May 15; 77(6):647-653. PubMed ID: 28102015
    [Abstract] [Full Text] [Related]

  • 8. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, Fiorentino M, Mucci LA.
    Eur Urol; 2019 Jul 15; 76(1):33-40. PubMed ID: 30301696
    [Abstract] [Full Text] [Related]

  • 9. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A, Saramäki OR, Zlobec I, Rotzer D, Genitsch V, Seiler R, Visakorpi T, Thalmann GN.
    Prostate; 2014 Dec 15; 74(16):1647-54. PubMed ID: 25252136
    [Abstract] [Full Text] [Related]

  • 10. Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.
    Graff RE, Meisner A, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA, Pettersson A.
    Br J Cancer; 2016 Apr 12; 114(8):939-44. PubMed ID: 26986253
    [Abstract] [Full Text] [Related]

  • 11. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J.
    Cancer Res; 2006 Nov 15; 66(22):10658-63. PubMed ID: 17108102
    [Abstract] [Full Text] [Related]

  • 12. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
    Egbers L, Luedeke M, Rinckleb A, Kolb S, Wright JL, Maier C, Neuhouser ML, Stanford JL.
    Am J Epidemiol; 2015 May 01; 181(9):706-13. PubMed ID: 25852077
    [Abstract] [Full Text] [Related]

  • 13. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
    Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.
    Cancer Res; 2009 Jan 15; 69(2):640-6. PubMed ID: 19147579
    [Abstract] [Full Text] [Related]

  • 14. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
    Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA.
    Oncogene; 2007 Jul 05; 26(31):4596-9. PubMed ID: 17237811
    [Abstract] [Full Text] [Related]

  • 15. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD.
    Dan Med J; 2016 Dec 05; 63(12):. PubMed ID: 27910803
    [Abstract] [Full Text] [Related]

  • 16. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.
    Neoplasia; 2006 Oct 05; 8(10):885-8. PubMed ID: 17059688
    [Abstract] [Full Text] [Related]

  • 17. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.
    Krstanoski Z, Vokac NK, Zagorac A, Pospihalj B, Munda M, Dzeroski S, Golouh R.
    BMC Urol; 2016 Jul 04; 16(1):35. PubMed ID: 27377958
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
    Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, Sridhar SS, Knox JJ, Day JR, Groskopf J, Joshua AM.
    BJU Int; 2012 Sep 04; 110(6):840-5. PubMed ID: 22313860
    [Abstract] [Full Text] [Related]

  • 19. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
    Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C.
    Cancer Epidemiol Biomarkers Prev; 2009 Nov 04; 18(11):3030-5. PubMed ID: 19861517
    [Abstract] [Full Text] [Related]

  • 20. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
    Wang J, Cai Y, Ren C, Ittmann M.
    Cancer Res; 2006 Sep 01; 66(17):8347-51. PubMed ID: 16951141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.